-
Clinical Trials & Development5 days agoTozorakimab Demonstrated Statistically Significant and Highly Clinically Meaningful Reduction in COPD Exacerbations in OBERON and TITANIA Phase III Trials
September 8, 2026 -- Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant...
-
Clinical Trials & Development5 days ago
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel
PRINCETON, N.J.--(BUSINESS WIRE) September 08, 2026 -- Bristol Myers Squibb (NYSE: BMY) today announced positive Phase 2 results from the registrational QUINTESSENTIAL trial (NCT06297226) of arlocabtagene...
-
Clinical Trials & Development5 days ago
Novartis Provides Update on Delpacibart Etedesiran (del-desiran) Phase III HARBOR Study for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Basel, September 8, 2026 – Novartis today announced that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1)...
-
Clinical Trials & Development5 days agoInhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the...
-
Clinical Trials & Development5 days agoRoivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage...
-
Clinical Trials & Development5 days ago
Eight Trends Reshaping Patient-Centric Drug Development
Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and...
-
Clinical Trials & Development5 days agoPrediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
-
Clinical Trials & Development5 days agoNovartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in...
-
Clinical Trials & Development5 days agoNovartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular...
-
Clinical Trials & Development5 days agoSTAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
